We have recently shown that by using a combined a marker‐dependent (CSPG4 and CD146MACS microbeads) and marker‐independent (Parsortix, Angle plc) detection method, 32% of patients were CTC‐positive with an increase in CTC‐positivity with increased tumor staging (Gorges et al., 2019). Here, CSPG4 is linked to neoplasm.